BioSig Technologies announces intent to acquire Nuero-Kinesis assets

BioSig Technologies announced the intent to acquire the assets of Neuro-Kinesis Corporation, a privately held Los Angeles-based medical technology company developing smart EP tools A non-binding letter of intent has been executed confirming BioSig’s preliminary interest in the proposed acquisition of the assets of NKC. The purchase price will be paid through the issuance of shares of BioSig’s common stock to the shareholders of NKC. In addition, at closing, NKC will provide a minimum of $2.5 million, but could provide up to $6 million, of unrestricted cash to BioSig. The proposed acquisition will require extensive due diligence, potentially through year-end, with full disclosures in the Company’s next proxy statement for shareholder vote.